Skip to content

Better Tests- Improving Diagnostic Accuracy and Prognostication in Interstitial Lung Diseases

Better Tests- Improving Diagnostic Accuracy and Prognostication in Interstitial Lung Diseases

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07615504
Acronym
Better Tests
Enrollment
750
Registered
2026-05-29
Start date
2026-01-17
Completion date
2036-01-15
Last updated
2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Disease (ILD)

Keywords

Interstitial Lung Disease, Lung fibrosis, Non-invasive assessment, Pigeon fanciers, Prognostication, Diagnosis

Brief summary

Patients with interstitial lung diseases (ILD) suffer significant delays in obtaining a diagnosis, and objective evidence of support for immunosuppressive therapies, due to weaknesses in the diagnostic tests available in ILD clinics. This project will assess several non-invasive assessments, focusing on blood and breath based sampling, to identify candidate tests that may translate through to routine clinical use. The tests being assessed will be initially employed in Pigeon Fanciers, a group recognised to be at high risk of developing ILD compared to age matched controls, due to their regular exposure to a known cause of ILD. Candidate tests will also be assessed for change over time in this group. Tests which show promise will then be utilised in patients with ILD diagnoses, including those with severe respiratory failure, to assess their acceptability to patients and their ability to provide useful prognostic information, to allow powering of future definitive clinical trials.

Detailed description

Pigeon Fanciers attending a recruitment event at one of the large national meetings for the sport will undergo assessments after completion of informed consent. The basic assessments include collection of height, weight and lung function (e.g. spirometry). In addition we will collect basic information about current health, past medical history and current pigeon keeping habits (number kept, time spent with birds etc). Participants will then have a blood sample taken for collection of antibody level against Pigeons, and for storage for subsequent processing of relevant candidate objective tests. Participants will also perform an additional breathing test to allow collection of exhaled air, which will be analysed on site or via subsequent testing (dependent on test required). Results will be linked to symptoms on exposure to their pigeons and any subsequent diagnoses obtained. Subsequent follow up of the Pigeon Fancier cohort, again via the participants attendance at large national meetings, will allow repeat of the candidate tests, enabling determination of natural variation and the effect of change in exposure or development of new medical conditions. We will also examine the dynamic change in candidate tests following natural exposures to causes of ILD, by performing the tests with a subset of Pigeon Fanciers before, during and after exposure to their birds. Patients attending Interstitial Lung Disease clinics in NHS Tayside, and when admitted with their Interstitial Lung Disease, will be offered the opportunity to perform the non-invasive assessments available to Pigeon Fanciers, with their results being linked to subsequent clinical outcomes (progression of disease, response to treatment and time to death).

Interventions

None listed

Sponsors

University of Dundee
Lead SponsorOTHER
British Pigeon Fanciers Medical Research
CollaboratorUNKNOWN
NHS Tayside
CollaboratorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

To participate subjects will either have to be active Pigeon Fanciers, or will be either attending ILD clinics for management of their interstitial lung disease or will present acutely to hospital services with severe respiratory failure due to ILD.

Exclusion criteria

Unable to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Prediction of subsequent clinical outcomes5 yearsThe utilised tests will be examined for their ability to accurately predict the subsequent diagnostic label for ILD and clinical behaviour
Acceptability to participants5 yearsThe tests employed will be assessed for their ease of performance and acceptability from a participant perspective

Countries

United Kingdom

Contacts

CONTACTMark Spears, PhD FRCP
mspears001@dundee.ac.uk+44 1738 473861
PRINCIPAL_INVESTIGATORMark Spears, PhD FRCP

NHS Tayside and University of Dundee

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 30, 2026